FY2026 EPS Estimate for Connect Biopharma Lifted by Analyst

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB – Free Report) – Equities research analysts at HC Wainwright raised their FY2026 EPS estimates for Connect Biopharma in a report issued on Tuesday, November 17th. HC Wainwright analyst B. Folkes now expects that the company will earn ($1.11) per share for the year, up from their prior forecast of ($1.17). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Connect Biopharma’s current full-year earnings is ($1.05) per share. HC Wainwright also issued estimates for Connect Biopharma’s FY2027 earnings at ($0.63) EPS, FY2028 earnings at ($0.90) EPS, FY2029 earnings at ($1.05) EPS and FY2030 earnings at ($1.11) EPS.

Connect Biopharma (NASDAQ:CNTB – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). The business had revenue of $0.74 million for the quarter, compared to analyst estimates of $9.65 million.

Several other research analysts also recently weighed in on the company. BTIG Research dropped their target price on Connect Biopharma to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, September 30th. Wall Street Zen cut Connect Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. Weiss Ratings cut Connect Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. Oppenheimer lowered their price target on Connect Biopharma to $5.00 and set an “outperform” rating for the company in a report on Tuesday, September 22nd. Finally, Canaccord Genuity Group restated a “buy” rating on shares of Connect Biopharma in a research note on Tuesday. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Connect Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $5.88.

Get Our Latest Stock Analysis on Connect Biopharma

Connect Biopharma Stock Performance

Shares of CNTB opened at $0.59 on Thursday. Connect Biopharma has a 12 month low of $0.55 and a 12 month high of $3.82. The stock has a fifty day moving average price of $0.91 and a 200-day moving average price of $2.06. The company has a current ratio of 2.37, a quick ratio of 2.37 and a debt-to-equity ratio of 0.01. The firm has a market cap of $37.15 million, a PE ratio of -0.52 and a beta of 0.06.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. ADAR1 Capital Management LLC purchased a new stake in shares of Connect Biopharma during the first quarter valued at $1,945,000. BML Capital Management LLC raised its stake in Connect Biopharma by 574.1% in the 3rd quarter. BML Capital Management LLC now owns 3,864,400 shares of the company’s stock worth $4,251,000 after acquiring an additional 3,291,113 shares during the last quarter. Marshall Wace LLP raised its stake in Connect Biopharma by 12.0% in the 3rd quarter. Marshall Wace LLP now owns 376,029 shares of the company’s stock worth $414,000 after acquiring an additional 40,387 shares during the last quarter. Bank of America Corp DE purchased a new position in Connect Biopharma in the 1st quarter worth $41,000. Finally, Knott David M Jr lifted its position in Connect Biopharma by 93.9% during the 1st quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after acquiring an additional 187,835 shares during the period. Hedge funds and other institutional investors own 58.72% of the company’s stock.

About Connect Biopharma

(Get Free Report)

Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.

Recommended Stories

Earnings History and Estimates for Connect Biopharma (NASDAQ:CNTB)

Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.